Campath-1G

Campath IgG, Campath-1-IgG Antibody

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994 May; 13: 597–611
PubMed CAS Google Scholar
Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995 Mar; 15: 387–93
PubMed CAS Google Scholar
Varadi G, Or R, Rund D, et al. Severe migratory polyarthritis following in vivo CAMPATH-1G. Bone Marrow Transplant 1995 Dec; 16: 843–5
PubMed CAS Google Scholar
Arnold R, Bunjes D, Wiesneth M, et al. In vitro and in vivo depletion of T cells. Bone Marrow Transplant 1993; 12 Suppl. 3: 11–2
Google Scholar
Jacobs P, Wood L, Waldmann H, et al. T-cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Exper Hematol 1994 Aug; 22: 679
Google Scholar

Campath-1G. Drugs R&D 1, 71–72 (1999). https://doi.org/10.2165/00126839-199901010-00023

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.